Search

everythinglearnresearchcommunity

for

Search:↓

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The user experienced hair regrowth using a combination of Minoxidil, Finasteride, and RU58841, with Minoxidil used initially and the other treatments added later. The user believes the combination of Finasteride and RU58841 contributed to the regrowth, with RU sourced from MVsupplement.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

RU58841's potential toxicity to cats is uncertain, similar to minoxidil. Caution is advised to prevent accidental exposure to pets.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

OP believes RU58841 affected their thyroid, causing hypothyroidism and impacting minoxidil's effectiveness. They plan to start thyroid medication to improve hair regrowth.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

The user is experiencing hair loss and has tried various treatments including topical and oral finasteride, minoxidil, dutasteride, and ketoconazole, but continues to lose hair. They are considering alternative solutions like hair systems due to the lack of improvement and a scalp condition called CVG.

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

The conversation discusses the effects of Pyrilutamide on hair growth after two months, with one person noting that while new hair regrowth isn't apparent, existing hair appears longer and thicker.

The individual is experiencing hair loss due to insulin resistance (IR) and is seeking advice. They are currently using a keto diet, supplements, exercise, and plan to add metformin to their regimen.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

Using Pyrilutamide or RU as monotherapy for hair loss? Share experiences.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.

The user has been using Pyrilutamide (Pyril) for hair loss for a month alongside finasteride/dutasteride since 2021 but hasn't seen results. They are considering switching to RU58841 due to its many success stories, despite being skeptical about the legitimacy and testing of Pyrilutamide.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

Loose-Message9596 has been experiencing hair loss for 3-4 years, initially due to low ferritin and vitamin D levels, and has tried treatments like vitamins, System 4, and PRP therapy. They are considering starting finasteride and minoxidil but are unsure due to their relatively low DHT level of 425.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.

A potential update on the progress of pyrilutamide, a hair loss treatment; and if Kintor should stop their trials.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.